RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals Equity 2024

Kiniksa Pharmaceuticals Equity

438.84 M USD

Ticker

KNSA

ISIN

BMG5269C1010

WKN

A2JMVJ

In 2024, Kiniksa Pharmaceuticals's equity was 438.84 M USD, a 10.79% increase from the 396.1 M USD equity in the previous year.

Kiniksa Pharmaceuticals Aktienanalyse

What does Kiniksa Pharmaceuticals do?

Kiniksa Pharmaceuticals Ltd is a US biotech company founded in 2015 and headquartered in Lexington, Massachusetts. The company specializes in the development and commercialization of therapies for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals' business model is based on collaboration with leading scientists and clinicians to develop innovative solutions for patients with complex clinical needs. The company's products focus on various inflammatory diseases and have multiple candidates in the pipeline for different indications in clinical development. Kiniksa Pharmaceuticals has also focused on developing therapies for rare diseases. A key feature of the company is its high-throughput platform, which allows for the identification and validation of potential therapeutics in a short amount of time. Kiniksa Pharmaceuticals was founded in 2015 by former executives from Biogen and Vertex Pharmaceuticals who had extensive experience in the discovery and development of drugs for chronic inflammatory diseases. The company quickly received an initial funding of $60 million and has since sought additional financing to expand its technology platform and scientific expertise. Kiniksa Pharmaceuticals consists of several divisions, including the development division, which is responsible for the clinical development of therapeutics for rare and chronic inflammatory diseases. Another important division is product development, which specializes in the identification and validation of candidates for potential therapeutics. This includes the identification of biomarkers that can serve as indicators of drug effectiveness. Kiniksa Pharmaceuticals also has a marketing division responsible for the commercialization of already approved products. The products of Kiniksa Pharmaceuticals focus on the treatment of inflammatory diseases. One of the key candidates currently in clinical development is KPL-716, a potential monoclonal antibody that can be used for multiple indications, including cutaneous T-cell lymphoma and chronic obstructive asthma. Another important potential is the candidate Mavrilimumab, a potential monoclonal antibody that can be used for the treatment of giant cell arteritis and polymyalgia rheumatica. Other key candidates include KPL-404, a potential monoclonal antibody that can be used for the treatment of ulcerative colitis. Overall, Kiniksa Pharmaceuticals has a promising future by focusing on innovative products for rare and chronic inflammatory diseases. Kiniksa Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Kiniksa Pharmaceuticals's Equity

Kiniksa Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kiniksa Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kiniksa Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kiniksa Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kiniksa Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kiniksa Pharmaceuticals stock

What is the equity of Kiniksa Pharmaceuticals this year?

Kiniksa Pharmaceuticals has equity of 438.84 M USD this year.

What was the equity of Kiniksa Pharmaceuticals compared to the previous year?

The equity of Kiniksa Pharmaceuticals has increased/decreased by 10.79% increased compared to the previous year.

What impact does a high equity have on investors of Kiniksa Pharmaceuticals?

A high equity is advantageous for investors of Kiniksa Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Kiniksa Pharmaceuticals?

A low equity can be a risk for investors of Kiniksa Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Kiniksa Pharmaceuticals affect the company?

An increase in equity of Kiniksa Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Kiniksa Pharmaceuticals affect the company?

A reduction in equity of Kiniksa Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Kiniksa Pharmaceuticals?

Some factors that can affect the equity of Kiniksa Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Kiniksa Pharmaceuticals so important for investors?

The equity of Kiniksa Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Kiniksa Pharmaceuticals take to change the equity?

To change equity, Kiniksa Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Kiniksa Pharmaceuticals pay?

Over the past 12 months, Kiniksa Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiniksa Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Kiniksa Pharmaceuticals?

The current dividend yield of Kiniksa Pharmaceuticals is .

When does Kiniksa Pharmaceuticals pay dividends?

Kiniksa Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Kiniksa Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiniksa Pharmaceuticals located?

Kiniksa Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiniksa Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiniksa Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Kiniksa Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Kiniksa Pharmaceuticals in the year 2023?

In the year 2023, Kiniksa Pharmaceuticals distributed 0 USD as dividends.

In which currency does Kiniksa Pharmaceuticals pay out the dividend?

The dividends of Kiniksa Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kiniksa Pharmaceuticals

Our stock analysis for Kiniksa Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiniksa Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.